1. Home
  2. CRBP vs BSL Comparison

CRBP vs BSL Comparison

Compare CRBP & BSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$7.88

Market Cap

190.3M

Sector

Health Care

ML Signal

HOLD

Logo Blackstone

BSL

Blackstone

HOLD

Current Price

$13.04

Market Cap

168.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBP
BSL
Founded
2009
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
168.7M
IPO Year
2014
2010

Fundamental Metrics

Financial Performance
Metric
CRBP
BSL
Price
$7.88
$13.04
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$45.50
N/A
AVG Volume (30 Days)
991.2K
51.0K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
9.55%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,822,272.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$116.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
97.62
N/A
52 Week Low
$6.33
$12.45
52 Week High
$20.56
$14.14

Technical Indicators

Market Signals
Indicator
CRBP
BSL
Relative Strength Index (RSI) 34.64 55.14
Support Level $7.62 $12.87
Resistance Level $8.54 $13.14
Average True Range (ATR) 0.74 0.06
MACD -0.26 0.01
Stochastic Oscillator 26.45 86.67

Price Performance

Historical Comparison
CRBP
BSL

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About BSL Blackstone

Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.

Share on Social Networks: